Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE
NCT ID: NCT00730860
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
140 participants
INTERVENTIONAL
2009-12-31
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
NCT00556803
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
NCT01415063
Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
NCT00554905
Radiofrequency-assisted Liver Resection in Intractable Liver Cancer
NCT04413526
TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
NCT03636620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RFA+TACE
treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
radiofrequency ablation associated with TACE
treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
RFA only
treatment of hepatocellular carcinoma by radiofrequency ablation only
radiofrequency ablation only
treatment of hepatocellular carcinoma by radiofrequency ablation only
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
radiofrequency ablation associated with TACE
treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
radiofrequency ablation only
treatment of hepatocellular carcinoma by radiofrequency ablation only
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with a live function test showed Child A or B
* Indocyanine green test showed less than 30％ after 15min,and the patients showed a tolerance of RFA and TACE
* Tumor stage is early period(according to Milan Standard),that is,the diameter of single node should be less than 5cm；the node of tumor should be less than 3 and the diameter less than 3cm.
* without metastasis in lymphnode or other organs
* written consent inform assigned
Exclusion Criteria
* metastatic cancer of liver
* patients with a poor tolerance of RFA and TACE
* patients received other therapies.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agency for Science, Technology and Research
OTHER
Southwest Hospital, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
feng xiaobin
Dr Xiaobin Feng
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ma Kuansheng, Ph.D
Role: STUDY_DIRECTOR
Institute of hepatobiliary surgery,Southwest Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of hepatobiliary surgery
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SWHB002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.